Skip to content

Study · Observational study · n = 367 · 2025

11 results

Oral versus subcutaneous semaglutide weight loss outcomes after two years among patients with type 2 diabetes in a real-world database.

Kwon J, Thiara D, Watanabe JH

Expert review of endocrinology & metabolism7 Feb 2025Cited by 6 (Europe PMC)

PMID39921267 (opens in a new tab)DOI10.1080/17446651.2025.2462100 (opens in a new tab)PepBankPUB-39921267
Publisher pagePubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, mean percentage weight change differed significantly between subcutaneous and oral semaglutide, with more weight loss on the subcutaneous form.

    In plain wordsIn adults with type 2 diabetes, injected semaglutide led to more weight loss than oral semaglutide over 2 years.

    Peptide
    Semaglutide
    Outcome
    DecreaseMean percentage weight change, subcutaneous versus oral
    Study

    n = 367

    Comparator
    Oral semaglutide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous and oral · 2 yearsAs given in this study (human).

    Source sentences

    Summary
    Significant differences existed between formulations in mean percentage weight change (p-value <0.01)
    3 context sentences
    Summary · context
    Subcutaneous users achieved superior weight loss compared to oral users.
    Summary · context
    This retrospective cohort study compared effectiveness of oral and subcutaneous semaglutide for weight loss outcomes in adults with type 2 diabetes (T2D) over a 2-year treatment period.
    Summary · context
    Weight loss was evaluated through mean percentage change from baseline, proportion achieving at least 5% weight loss and at least 10% weight loss comparing subcutaneous (n = 310) versus oral users (n = 57) and by age group.
  2. 02HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, a larger proportion achieved at least 10% weight loss with subcutaneous than with oral semaglutide.

    In plain wordsIn adults with type 2 diabetes, more people lost at least 10% of their weight on injected than on oral semaglutide.

    Peptide
    Semaglutide
    Outcome
    IncreaseProportion with at least 10% weight loss, subcutaneous versus oral
    Study

    n = 367

    Comparator
    Oral semaglutide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous and oral · 2 yearsAs given in this study (human).

    Source sentences

    Summary
    and proportion achieving ≥10% loss (p-value = 0.03)
    2 context sentences
    Summary · context
    This retrospective cohort study compared effectiveness of oral and subcutaneous semaglutide for weight loss outcomes in adults with type 2 diabetes (T2D) over a 2-year treatment period.
    Summary · context
    Weight loss was evaluated through mean percentage change from baseline, proportion achieving at least 5% weight loss and at least 10% weight loss comparing subcutaneous (n = 310) versus oral users (n = 57) and by age group.
  3. 03HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, the proportion achieving at least 5% weight loss did not differ significantly between subcutaneous and oral semaglutide.

    In plain wordsIn adults with type 2 diabetes, the share of people losing at least 5% of weight was not clearly different between injected and oral semaglutide.

    Peptide
    Semaglutide
    Outcome
    No significant changeProportion with at least 5% weight loss, subcutaneous versus oral
    Study

    n = 367

    Comparator
    Oral semaglutide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous and oral · 2 yearsAs given in this study (human).

    Source sentences

    Summary
    but not in proportion achieving ≥5% loss (p-value = 0.34)
    2 context sentences
    Summary · context
    This retrospective cohort study compared effectiveness of oral and subcutaneous semaglutide for weight loss outcomes in adults with type 2 diabetes (T2D) over a 2-year treatment period.
    Summary · context
    Weight loss was evaluated through mean percentage change from baseline, proportion achieving at least 5% weight loss and at least 10% weight loss comparing subcutaneous (n = 310) versus oral users (n = 57) and by age group.
  4. 04HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, regression analyses adjusted for confounders gave findings similar to the unadjusted comparison of subcutaneous and oral semaglutide.

    In plain wordsIn adults with type 2 diabetes, adjusting for other factors gave similar results when comparing injected with oral semaglutide.

    Peptide
    Semaglutide
    Outcome
    Not applicableAdjusted regression of formulation differences
    Study

    n = 367

    Comparator
    Oral semaglutide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous and oral · 2 yearsAs given in this study (human).

    Source sentences

    Summary
    Regression analyses adjusted for confounders yielded similar findings.
    2 context sentences
    Summary · context
    This retrospective cohort study compared effectiveness of oral and subcutaneous semaglutide for weight loss outcomes in adults with type 2 diabetes (T2D) over a 2-year treatment period.
    Summary · context
    Weight loss was evaluated through mean percentage change from baseline, proportion achieving at least 5% weight loss and at least 10% weight loss comparing subcutaneous (n = 310) versus oral users (n = 57) and by age group.
  5. 05HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, subcutaneous semaglutide users lost a mean of 7.5% of body weight over 2 years.

    In plain wordsIn adults with type 2 diabetes, people using injected semaglutide lost on average 7.5% of their body weight over 2 years.

    Peptide
    Semaglutide
    Outcome
    DecreaseMean percentage weight change, subcutaneous semaglutide
    Study

    n = 310

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 2 yearsAs given in this study (human).

    Measurements

    Mean weight change
    7.5%
    subcutaneous
    Mean weight change
    16.7 pounds
    subcutaneous

    Source sentences

    Summary
    Subcutaneous users experienced a mean percentage weight loss of 7.5% (16.7 pounds)
    2 context sentences
    Summary · context
    This retrospective cohort study compared effectiveness of oral and subcutaneous semaglutide for weight loss outcomes in adults with type 2 diabetes (T2D) over a 2-year treatment period.
    Summary · context
    Weight loss was evaluated through mean percentage change from baseline, proportion achieving at least 5% weight loss and at least 10% weight loss comparing subcutaneous (n = 310) versus oral users (n = 57) and by age group.
  6. 06HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, 58.7% of subcutaneous semaglutide users achieved at least 5% weight loss over 2 years.

    In plain wordsIn adults with type 2 diabetes, 58.7% of people on injected semaglutide lost at least 5% of their weight over 2 years.

    Peptide
    Semaglutide
    Outcome
    Not applicableProportion with at least 5% weight loss, subcutaneous
    Study

    n = 310

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 2 yearsAs given in this study (human).

    Measurements

    Proportion with weight loss >=5%
    58.7%
    subcutaneous

    Source sentences

    Summary
    with 58.7% and 32.9% achieving ≥5% and ≥10% loss, respectively.
    2 context sentences
    Summary · context
    This retrospective cohort study compared effectiveness of oral and subcutaneous semaglutide for weight loss outcomes in adults with type 2 diabetes (T2D) over a 2-year treatment period.
    Summary · context
    Weight loss was evaluated through mean percentage change from baseline, proportion achieving at least 5% weight loss and at least 10% weight loss comparing subcutaneous (n = 310) versus oral users (n = 57) and by age group.
  7. 07HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, 32.9% of subcutaneous semaglutide users achieved at least 10% weight loss over 2 years.

    In plain wordsIn adults with type 2 diabetes, 32.9% of people on injected semaglutide lost at least 10% of their weight over 2 years.

    Peptide
    Semaglutide
    Outcome
    Not applicableProportion with at least 10% weight loss, subcutaneous
    Study

    n = 310

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 2 yearsAs given in this study (human).

    Measurements

    Proportion with weight loss >=10%
    32.9%
    subcutaneous

    Source sentences

    Summary
    with 58.7% and 32.9% achieving ≥5% and ≥10% loss, respectively.
    2 context sentences
    Summary · context
    This retrospective cohort study compared effectiveness of oral and subcutaneous semaglutide for weight loss outcomes in adults with type 2 diabetes (T2D) over a 2-year treatment period.
    Summary · context
    Weight loss was evaluated through mean percentage change from baseline, proportion achieving at least 5% weight loss and at least 10% weight loss comparing subcutaneous (n = 310) versus oral users (n = 57) and by age group.
  8. 08HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, oral semaglutide users lost a mean of 4.4% of body weight over 2 years.

    In plain wordsIn adults with type 2 diabetes, people using oral semaglutide lost on average 4.4% of their body weight over 2 years.

    Peptide
    Semaglutide
    Outcome
    DecreaseMean percentage weight change, oral semaglutide
    Study

    n = 57

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · oral · 2 yearsAs given in this study (human).

    Measurements

    Mean weight change
    4.4%
    oral
    Mean weight change
    8.7 pounds
    oral

    Source sentences

    Summary
    Oral users lost 4.4% (8.7 pounds) with 50.9% and 17.5% achieving ≥5% and ≥10% loss, respectively.
    2 context sentences
    Summary · context
    This retrospective cohort study compared effectiveness of oral and subcutaneous semaglutide for weight loss outcomes in adults with type 2 diabetes (T2D) over a 2-year treatment period.
    Summary · context
    Weight loss was evaluated through mean percentage change from baseline, proportion achieving at least 5% weight loss and at least 10% weight loss comparing subcutaneous (n = 310) versus oral users (n = 57) and by age group.
  9. 09HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, 50.9% of oral semaglutide users achieved at least 5% weight loss over 2 years.

    In plain wordsIn adults with type 2 diabetes, 50.9% of people on oral semaglutide lost at least 5% of their weight over 2 years.

    Peptide
    Semaglutide
    Outcome
    Not applicableProportion with at least 5% weight loss, oral
    Study

    n = 57

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · oral · 2 yearsAs given in this study (human).

    Measurements

    Proportion with weight loss >=5%
    50.9%
    oral

    Source sentences

    Summary
    Oral users lost 4.4% (8.7 pounds) with 50.9% and 17.5% achieving ≥5% and ≥10% loss, respectively.
    2 context sentences
    Summary · context
    This retrospective cohort study compared effectiveness of oral and subcutaneous semaglutide for weight loss outcomes in adults with type 2 diabetes (T2D) over a 2-year treatment period.
    Summary · context
    Weight loss was evaluated through mean percentage change from baseline, proportion achieving at least 5% weight loss and at least 10% weight loss comparing subcutaneous (n = 310) versus oral users (n = 57) and by age group.
  10. 10HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, 17.5% of oral semaglutide users achieved at least 10% weight loss over 2 years.

    In plain wordsIn adults with type 2 diabetes, 17.5% of people on oral semaglutide lost at least 10% of their weight over 2 years.

    Peptide
    Semaglutide
    Outcome
    Not applicableProportion with at least 10% weight loss, oral
    Study

    n = 57

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · oral · 2 yearsAs given in this study (human).

    Measurements

    Proportion with weight loss >=10%
    17.5%
    oral

    Source sentences

    Summary
    Oral users lost 4.4% (8.7 pounds) with 50.9% and 17.5% achieving ≥5% and ≥10% loss, respectively.
    2 context sentences
    Summary · context
    This retrospective cohort study compared effectiveness of oral and subcutaneous semaglutide for weight loss outcomes in adults with type 2 diabetes (T2D) over a 2-year treatment period.
    Summary · context
    Weight loss was evaluated through mean percentage change from baseline, proportion achieving at least 5% weight loss and at least 10% weight loss comparing subcutaneous (n = 310) versus oral users (n = 57) and by age group.
  11. 11HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes taking oral semaglutide, weight loss outcomes differed by age group.

    In plain wordsIn adults with type 2 diabetes, weight loss on oral semaglutide differed between age groups.

    Peptide
    Semaglutide
    Outcome
    MixedWeight outcomes by age group, oral semaglutide
    Study

    n = 57

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · oral · 2 yearsAs given in this study (human).

    Source sentences

    Summary
    Outcomes differed by age within oral semaglutide (p-value = 0.02).
    2 context sentences
    Summary · context
    This retrospective cohort study compared effectiveness of oral and subcutaneous semaglutide for weight loss outcomes in adults with type 2 diabetes (T2D) over a 2-year treatment period.
    Summary · context
    Weight loss was evaluated through mean percentage change from baseline, proportion achieving at least 5% weight loss and at least 10% weight loss comparing subcutaneous (n = 310) versus oral users (n = 57) and by age group.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.